Key Highlights
- METiS Secures RMB 400 Million in Series D Round to Accelerate AI-Enabled Nanodelivery and Expand Global Partnerships
The funding, co-led by Beijing Medical and Health Industry Investment Fund and Daxing Industrial Investment Fund, fuels automation upgrades, pipeline development, and talent acquisition. - Integration into Beijing’s OpenCGT Platform Positions METiS as a Core Pillar for Precision Cell and Gene Therapy Commercialization
Combining proprietary AI technologies with nanomaterial science, METiS advances clinical translation of next-generation therapies, including liver-targeted CRISPR gene-editing delivery. - Government Backing and Strategic Fund Commitments Highlight China’s Commitment to AI-Integrated Life Sciences Innovation
The city’s Three-Year Action Plan aims to foster a globally recognized innovation cluster, with METiS driving breakthroughs in AI-powered drug delivery for cancer, autoimmune, metabolic, and neurodegenerative diseases.
Strong Capital Infusion to Accelerate AI-Driven Nanotechnology Development
The recent RMB 400 million (~$57 million) financing round enables METiS to scale its AI-powered platform technologies—AiLNP for nucleic acid delivery system design, AiRNA for mRNA sequence optimization, and AiTEM for small molecule formulation. The investment supports automation, pipeline expansion, and deepening global collaborations.
Strategic Role in Beijing’s OpenCGT Life Sciences Ecosystem
METiS is a cornerstone of Beijing’s AI+Healthcare Innovation Action Plan and the OpenCGT platform, bridging academia, hospitals, and biotech firms to address challenges in precision nanodelivery and clinical translation of cell and gene therapies.
Cutting-Edge AI Platforms Delivering Next-Generation Therapeutic Solutions
Leveraging AI, quantum mechanics, and nanomaterial science, METiS simulates and optimizes nanoscale drug delivery interactions, enabling innovative treatments across diverse indications with improved efficacy and safety.
High-Level Support and Industry Ecosystem Strengthen Growth Trajectory
The financing’s lead investors represent Beijing’s commitment to healthcare innovation. METiS’ CEO Dr. Chris Lai highlights their mission to solve nanodelivery challenges through AI, supporting China’s leadership in CGT therapeutics by 2027.
For more information, visit METiS Technologies.
By
